What Researchers Did
Researchers examined 51 patients with glomerulonephritis, with 26 of them receiving hyperbaric oxygenation as part of their combined treatment.
What They Found
The study showed that adding hyperbaric oxygenation to multimodality treatment was clinically effective. It also led to positive changes in the lipid phase of cell membranes.
What This Means for Canadian Patients
For Canadian patients with glomerulonephritis, this research suggests hyperbaric oxygen therapy (HBOT) could potentially offer benefits when combined with other therapies. However, HBOT for glomerulonephritis is not a Health Canada-approved indication, meaning it is not a standard treatment option in Canada.
Canadian Relevance
No direct Canadian connection identified. Glomerulonephritis is not a Health Canada-recognized indication for hyperbaric oxygen therapy.
Study Limitations
This study was conducted with a small group of 51 patients and published in 1990, meaning its findings may not fully reflect current medical practices or larger patient populations.